Pfizer Inc. (PFE) to Issue Quarterly Dividend of $0.43 on June 12th

Pfizer Inc. (NYSE:PFE) declared a quarterly dividend on Wednesday, April 22nd. Shareholders of record on Friday, May 8th will be paid a dividend of 0.43 per share by the biopharmaceutical company on Friday, June 12th. This represents a c) annualized dividend and a yield of 6.5%. The ex-dividend date is Friday, May 8th.

Pfizer has decreased its dividend payment by an average of 0.1%per year over the last three years and has increased its dividend annually for the last 16 consecutive years. Pfizer has a dividend payout ratio of 55.8% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Pfizer to earn $2.82 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 61.0%.

Pfizer Stock Down 0.6%

Shares of NYSE PFE opened at $26.65 on Friday. Pfizer has a 52 week low of $21.97 and a 52 week high of $28.75. The business has a 50-day simple moving average of $27.24 and a two-hundred day simple moving average of $26.06. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The company has a market cap of $151.53 billion, a P/E ratio of 19.59 and a beta of 0.43.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm’s revenue was down 1.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.63 EPS. Research analysts anticipate that Pfizer will post 2.98 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on PFE shares. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, February 4th. Royal Bank Of Canada reiterated an “underperform” rating and set a $25.00 price target on shares of Pfizer in a research report on Monday. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a research report on Monday, March 2nd. HSBC lifted their price target on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Finally, UBS Group lifted their price target on Pfizer from $25.00 to $27.00 and gave the company a “neutral” rating in a research report on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $28.48.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.